Results 61 to 70 of about 2,495,766 (164)

The renin–angiotensin–aldosterone system blockade in patients with advanced diabetic kidney disease

Nefrología (English Edition), 2018
Background and objectives: Diabetic kidney disease is the leading cause of end-stage chronic kidney disease (CKD). The renin–angiotensin–aldosterone system (RAAS) blockade has been shown to slow the progression of diabetic kidney disease.
Sheila Bermejo, Carles Oriol García, Eva Rodríguez, Clara Barrios, Sol Otero, Sergi Mojal, Julio Pascual, María José Soler   +7 more
doaj   +1 more source

Epidemiología de la hiperpotasemia en la enfermedad renal crónica

Nefrología, 2019
Resumen: Antecedentes: La hiperpotasemia constituye un importante desequilibrio electrolítico en la enfermedad renal crónica (ERC). Los inhibidores del sistema renina-angiotensina-aldosterona (iSRAA) tienen propiedades beneficiosas cardiorrenales ...
Lara Belmar Vega, Emilio Rodrigo Galabia, Jairo Bada da Silva, Marta Bentanachs González, Gema Fernández Fresnedo, Celestino Piñera Haces, Rosa Palomar Fontanet, Juan Carlos Ruiz San Millán, Ángel Luis Martín de Francisco   +8 more
doaj   +1 more source

Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study. [PDF]

Arq Bras Cardiol, 2023
Shams E, Kamalumpundi V, Cheng L, Taiwo A, Shibli-Rahhal A, Dokun AO, Correia MLG.   +6 more
europepmc   +1 more source

ARRITMIAS EN EL PACIENTE HIPERTENSO: ¿CÓMO PREVENIRLAS?

Medicentro, 2011
La hipertensión arterial ejerce un efecto directo sobre el corazón que provoca hipertrofia del ventrículo izquierdo. Los mecanismos subcelulares de esta última involucran el sistema renina angiotensina aldosterona.
MSc. Dr. Elibet Chávez González, Dr. Emilio González Rodríguez, Lic. Raimundo Carmona Puerta, MSc. Dr. Ramiro Ramos Ramírez   +3 more
doaj  

Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. [PDF]

Rev Port Cardiol, 2023
Gonçalves J, Santos CD, Fresco P, Fernandez-Llimos F.   +3 more
europepmc   +1 more source

Dissociação da resposta anti-hipertensiva e metabólica à losartana e espironolactona em ratos com síndrome metabólica experimental

Brazilian Journal of Nephrology, 2012
INTRODUÇÃO: O tratamento da hipertensão arterial (HA) em indivíduos com síndrome metabólica (SM) é um desafio, uma vez que terapias não medicamentosas são de difícil implementação e o tratamento farmacológico ideal não está totalmente estabelecido ...
Hussen Machado, Helady Sanders Pinheiro, Marcella Martins Terra, Martha de Oliveira Guerra, Rogerio Baumgratz de Paula, Vera Maria Peters   +5 more
doaj   +1 more source

Impact of the withdrawal of renin-angiotensin-aldosterone inhibitors on mortality in COVID-19 patients. [PDF]

Rev Port Cardiol, 2022
Caro-Codón J, Rey JR, Iniesta AM, Rosillo SO, Castrejon-Castrejon S, Rodriguez-Sotelo L, Garcia-Veas JM, Marco I, Martinez LA, Martin-Polo L, Merino C, Martinez-Cossiani M, Buño A, Gonzalez-Valle L, Herrero A, López-de-Sá E, Merino JL, CARD-COVID Investigators (Appendix).   +17 more
europepmc   +1 more source

[Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors]. [PDF]

Med Clin (Barc), 2020
Golpe R, Pérez-de-Llano LA, Dacal D, Guerrero-Sande H, Pombo-Vide B, Ventura-Valcárcel P, Lugo Covid-19 team.   +6 more
europepmc   +2 more sources

EFICÁCIA DA 20-HIDROXIECDISONA ORAL (20E) EM ADULTOS COM COVID-19 GRAVE (COVA): UM ESTUDO RANDOMIZADO, CONTROLADO POR PLACEBO, DE FASE 2/3

Brazilian Journal of Infectious Diseases
Introdução: O SARS-CoV-2 infecta células humanas através da interação entre sua proteína spike e enzima Conversora de Angiotenciana-2 (ACE2), que é um elemento-chave do Sistema Renina-Angiotensina-Aldosterona (SRAA).
Estevão Portela Nunes, Adilson Joaquim Cavalcanti, Maria Lima Patelli, Fabiano Ramos, Ana Karolina Barreto Berselli Marinho, Ludmila Abrahão Hajjar, Suzana Margareth Lobo, Stanislas Veillet   +7 more
doaj   +1 more source

Epidemiology of hyperkalemia in chronic kidney disease

Nefrología (English Edition), 2019
Background: Hyperkalaemia is a significant electrolyte imbalance in chronic kidney disease (CKD). Renin–angiotensin–aldosterone system inhibitors (RAASi) have beneficial cardio-renal properties, although they can often cause hyperkalaemia.
Lara Belmar Vega, Emilio Rodrigo Galabia, Jairo Bada da Silva, Marta Bentanachs González, Gema Fernández Fresnedo, Celestino Piñera Haces, Rosa Palomar Fontanet, Juan Carlos Ruiz San Millán, Ángel Luis Martín de Francisco   +8 more
doaj   +1 more source